Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups

Introduction This post hoc pooled analysis of four real-world studies (SURE Canada, Denmark/Sweden, Switzerland and UK) aimed to characterize the use of once-weekly (OW) semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D). Research design and methods The Semaglutide Real-world Evidence (SURE) studies had a duration of similar to 30 weeks. Changes in glycated hemoglobin (HbA(1c)) and body weight (BW) were analyzed for the overall population and the following baseline subgroups: GLP-1RA-naive/GLP-1RA switchers; body mass index <25/>= 25-<30/>= 30-<35/>= 35 kg/m(2); age <65/>= 65 years; HbA(1c) <7%/>= 7-<= 8%/>8-<= 9%/>9%; T2D duration <5/>= 5-<10/>= 10 years. Data for patients achieving treatment targets were analyzed in the overall population and the baseline HbA(1c) >= 7% subgroup. Results Of 1212 patients, 960 were GLP-1RA-naive and 252 had switched to semaglutide from another GLP-1RA. In the overall population, HbA(1c) was reduced from baseline to end of study (EOS) by -1.1% point and BW by -4.7 kg; changes were significant for all subgroups. There were significantly larger reductions of HbA(1c) and BW in GLP-1RA-naive versus GLP-1RA switchers and larger reductions in HbA(1c) for patients with higher versus lower baseline HbA(1c). At EOS, 52.6% of patients in the overall population achieved HbA(1c) <7%. No new safety concerns were identified in any of the completed SURE studies. Conclusions In this pooled analysis, patients with T2D initiating OW semaglutide showed significant improvements from baseline to EOS in HbA(1c) and BW across various baseline subgroups, including patients previously treated with a GLP-1RA other than semaglutide, supporting OW semaglutide use in clinical practice.